# Phase 2 Uterine Cervical cancer trials: 105 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 105 trials in phase 2 for Uterine Cervical cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Uterine Cervical cancer trials: 105 rows for $5.25, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/uterine-cervical-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 105
- Recruiting or not yet: 105
- Read on: November 19, 2026

## Trials

The 25 newest of 105, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 18, 2026 | NCT07770100 | Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) | Sponsor not shown (see the record) | Phase 2 | Recruiting | Head and Neck Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer (GC) | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770100) |
| August 13, 2026 | NCT07763496 | Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer | ARCAGY/ GINECO GROUP | Phase 2 | Not yet recruiting | Recurrent or Metastatic Cervical Cancer | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763496) |
| July 28, 2026 | NCT07731828 | Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A... | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Cervical Neoplasms | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07731828) |
| June 16, 2026 | NCT07649174 | Cadonilimab Plus Chemotherapy in LACC: A Prospective, Multicenter, Randomized Phase II Trial | Obstetrics & Gynecology Hospital of Fudan University | Phase 2 | Not yet recruiting | Cervical Cancer | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649174) |
| June 12, 2026 | NCT07646301 | Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer | Sun Yat-sen University | Phase 2 | Recruiting | Uterine Cervical Neoplasms, Locally Advanced | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07646301) |
| June 8, 2026 | NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631884) |
| June 8, 2026 | NCT07631871 | An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm, Urothelial Carcinoma (UC), Pancreatic... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631871) |
| June 4, 2026 | NCT07627620 | Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer | Hunan Cancer Hospital | Phase 2 | Not yet recruiting | Cervical Cancer | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07627620) |
| June 3, 2026 | NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or... | GV20 Therapeutics | Phase 2 | Not yet recruiting | Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and... | 227 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623642) |
| June 1, 2026 | NCT07617818 | QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Not yet recruiting | Cervical Cancer, Neoadjuvant Therapy, Immunotherapy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617818) |
| May 14, 2026 | NCT07586826 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or... | Peking University People's Hospital | Phase 2 | Recruiting | Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586826) |
| May 8, 2026 | NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07576725) |
| April 22, 2026 | NCT07545746 | Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Not yet recruiting | HIV Infections, HPV Infection, Cervix Cancer, CIN2, CIN3, CIN1, CIN, Cervical Intraepithelial Neoplasia Grade 3... | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545746) |
| April 7, 2026 | NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 | Not yet recruiting | Cancer, Endometrial Cancer, Prostate Cancer, Cervical Cancer, Rectal Cancers | 264 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516210) |
| March 27, 2026 | NCT07497074 | JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 | Not yet recruiting | Cervical Cancer | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07497074) |
| March 3, 2026 | NCT07446049 | A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the... | Convalife (Shanghai) Co., Ltd. | Phase 2 | Not yet recruiting | Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07446049) |
| February 27, 2026 | NCT07439497 | Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer | Samsung Medical Center | Phase 2 | Recruiting | Cervical Cancer | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07439497) |
| February 27, 2026 | NCT07435376 | Intra-lesional Tumor Boost for Bulky Cervical Cancer | Seoul National University Bundang Hospital | Phase 2 | Recruiting | Cervical Cancer, Squamous Cell Carcinoma of Cervix | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07435376) |
| February 20, 2026 | NCT07424664 | A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic... | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Recruiting | Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424664) |
| February 17, 2026 | NCT07415681 | GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries | University of Maryland, Baltimore | Phase 2 | Recruiting | Gynaecologic Cancer, Cervical Cancer, Radiation Therapy | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07415681) |
| February 12, 2026 | NCT07407647 | Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer | Ohio State University Comprehensive Cancer Center | Phase 2 | Recruiting | Anal Carcinoma, Cervical Carcinoma, Malignant Female Reproductive System Neoplasm, Rectal Carcinoma, Vaginal Carcinoma... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407647) |
| January 27, 2026 | NCT07368985 | Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2, Adenocarcinoma or... | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07368985) |
| January 23, 2026 | NCT07363330 | A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer | Zhongnan Hospital | Phase 2 | Not yet recruiting | Cervical Cancer, Recurrent, Metastatic | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07363330) |
| January 16, 2026 | NCT07348861 | A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Cervical Cancer | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07348861) |
| January 14, 2026 | NCT07340489 | Serplulimab for Locally Advanced Cervical Cancer | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Recruiting | Cervical Cancer | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07340489) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Obstetrics & Gynecology Hospital of Fudan University | 4 |
| Tianjin Medical University Cancer Institute and Hospital | 4 |
| Fujian Cancer Hospital | 3 |
| Tongji Hospital | 3 |
| Peking Union Medical College Hospital | 2 |
| Women's Hospital School Of Medicine Zhejiang University | 2 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 2 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 |
| Zhongnan Hospital | 2 |
| Sun Yat-sen University | 2 |
| Seoul National University Bundang Hospital | 1 |
| [Jiangsu Alphamab Biopharmaceuticals Co., Ltd](https://specstream.ai/data/clinical-trials/company/jiangsu-alphamab-biopharmaceuticals-co-ltd) | 1 |
| Maria Sklodowska-Curie National Research Institute of Oncology | 1 |
| Mayo Clinic | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| National Institute of Hygiene and Epidemiology, Vietnam | 1 |
| Vall d'Hebron Institute of Oncology | 1 |
| Fudan University | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| University of Utah | 1 |
| [Jiangsu HengRui Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd) | 1 |
| Stanford University | 1 |
| University of Aarhus | 1 |
| Instituto do Cancer do Estado de São Paulo | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 47 |
| United States | 25 |
| South Korea | 5 |
| Canada | 5 |
| Australia | 4 |
| Japan | 4 |
| Spain | 3 |
| Brazil | 3 |
| France | 3 |
| Taiwan | 3 |
| Germany | 3 |
| Italy | 3 |
| Netherlands | 2 |
| Vietnam | 2 |
| Denmark | 2 |
| Uganda | 2 |
| United Kingdom | 2 |
| Kenya | 1 |
| Iran | 1 |
| Austria | 1 |
| Belgium | 1 |
| Hungary | 1 |
| Norway | 1 |
| Mexico | 1 |
| Sierra Leone | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Apparel manufacturers in the United States](https://specstream.ai/data/businesses/apparel-manufacturers/united-states)
- [Pediatric clinics in the United States](https://specstream.ai/data/businesses/pediatric-clinics/united-states)
- [Equipment rental companies in the United States](https://specstream.ai/data/businesses/equipment-rental-companies/united-states)
- [Acoustical consultants in the United States](https://specstream.ai/data/businesses/acoustical-consultants/united-states)
- [Orthopedic surgery practices in the United States](https://specstream.ai/data/businesses/orthopedic-surgery-practices/united-states)
- [Electrical wholesalers in the United States](https://specstream.ai/data/businesses/electrical-wholesalers/united-states)
